Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Debt-to-Asset : 0.03 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Debt-to-Asset?

Reviva Pharmaceuticals Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.33 Mil. Reviva Pharmaceuticals Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Reviva Pharmaceuticals Holdings's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $13.50 Mil. Reviva Pharmaceuticals Holdings's debt to asset for the quarter that ended in Mar. 2024 was 0.02.

Reviva Pharmaceuticals Holdings Debt-to-Asset Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Debt-to-Asset Chart

Reviva Pharmaceuticals Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

1,255.00

Reviva Pharmaceuticals Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial													0.05	0.02	0.04	-	0.03

Competitive Comparison of Reviva Pharmaceuticals Holdings's Debt-to-Asset

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reviva Pharmaceuticals Holdings's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Debt-to-Asset falls into.

Reviva Pharmaceuticals Holdings Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Reviva Pharmaceuticals Holdings's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	23.7
	=	0.00

Reviva Pharmaceuticals Holdings's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.332	+	0)	/	13.497
	=	0.02

Reviva Pharmaceuticals Holdings (NAS:RVPHW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Reviva Pharmaceuticals Holdings Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPHW) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RVPH:USA

Address

19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014

Website

https://www.revivapharma.com

Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.